Holen Sie sich die Stockscreener-App
28.91
3.88%
1.0882
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BAX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$27.82
Offen:
$27.97
24-Stunden-Volumen:
1.67M
Relative Volume:
0.35
Marktkapitalisierung:
$14.73B
Einnahmen:
$17.28B
Nettoeinkommen (Verlust:
$108.00M
KGV:
144.54
EPS:
0.2
Netto-Cashflow:
$391.00M
1W Leistung:
+2.70%
1M Leistung:
-17.07%
6M Leistung:
-21.15%
1J Leistung:
-26.87%
1-Tages-Spanne:
$27.92
$28.97
1-Wochen-Bereich:
$26.78
$28.97
52-Wochen-Spanne:
$26.25
$41.18
Baxter International Inc Stock (BAX) Company Profile
Firmenname
Baxter International Inc
Sektor
Telefon
(847) 948-2000
Adresse
ONE BAXTER PKWY, DEERFIELD, IL
Vergleichen Sie BAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
28.84 | 14.73B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
486.85 | 173.82B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
200.73 | 57.28B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
92.31 | 45.42B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
213.87 | 31.24B | 4.93B | 1.25B | 1.38B | 8.47 |
|
COO
The Cooper Companies, Inc.
|
79.33 | 15.78B | 3.90B | 392.30M | 288.10M | 1.95 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-26 | Fortgesetzt | Goldman | Buy |
| 2025-02-24 | Hochstufung | Argus | Hold → Buy |
| 2025-02-20 | Fortgesetzt | Barclays | Overweight |
| 2024-07-15 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-05-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Eingeleitet | UBS | Neutral |
| 2023-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-06-24 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Herabstufung | Goldman | Neutral → Sell |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-18 | Bestätigt | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Bestätigt | Morgan Stanley | Overweight |
| 2022-02-18 | Bestätigt | Raymond James | Outperform |
| 2022-02-18 | Bestätigt | Stifel | Buy |
| 2022-02-18 | Bestätigt | UBS | Neutral |
| 2022-02-18 | Bestätigt | Wells Fargo | Overweight |
| 2022-02-11 | Eingeleitet | Goldman | Neutral |
| 2022-01-07 | Fortgesetzt | Citigroup | Buy |
| 2022-01-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-09-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2021-01-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Herabstufung | UBS | Buy → Neutral |
| 2020-12-15 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-09-04 | Herabstufung | Argus | Buy → Hold |
| 2020-06-24 | Eingeleitet | Oppenheimer | Outperform |
| 2020-03-19 | Hochstufung | Stifel | Hold → Buy |
| 2020-03-18 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-13 | Eingeleitet | Goldman | Buy |
| 2020-01-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-01-02 | Hochstufung | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Hochstufung | Argus | Hold → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Underweight |
| 2018-05-17 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-06 | Bestätigt | Citigroup | Neutral |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-03 | Hochstufung | Raymond James | Mkt Perform → Outperform |
Alle ansehen
Baxter International Inc Aktie (BAX) Neueste Nachrichten
The Latest Breaking News on Here's What to Expect From Baxter International’s Next Earnings Report - inkl
Here's What to Expect From Baxter International’s Next Earnings Report - TradingView
Dodge & Cox Buys 5,779,100 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Here's What To Expect From Baxter International’s Next Earnings Report - Barchart.com
Baxter International Inc. (NYSE:BAX) Shares Acquired by Jaffetilchin Investment Partners LLC - MarketBeat
Baxter to Host First-Quarter 2025 Financial Results Conference C - GuruFocus
Baxter to Host First-Quarter 2025 Financial Results Conference Call for Investors - The Joplin Globe
Latest Trends in Adhesion Barrier Market: 2024 to 2031 | Baxter - openPR.com
LSV Asset Management Has $159.96 Million Stake in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International (NYSE:BAX) Reaches New 1-Year LowShould You Sell? - MarketBeat
BAX Stock Declines Despite Latest Product Launch Boosting Patient Care - TradingView
Baxter International (BAX) Q3 2024 Earnings Call Transcript - Fortune
Russell Investments Group Ltd. Grows Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International (NYSE:BAX) Hits New 1-Year LowHere's Why - MarketBeat
Baxter International Enters Oversold Territory (BAX) - Nasdaq
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat for Rapid and Convenient Application During Surgery - PharmiWeb.com
Baxter Launches New Room Temperature Hemopatch Sealing Hemostat - GuruFocus
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL.com
Cullen Capital Management LLC Decreases Holdings in Baxter International Inc. (NYSE:BAX) - MarketBeat
Global Prefilled Syringes Market to Cross USD 28 Billion by 2032 | DelveInsight - GlobeNewswire Inc.
Breakthrough: Baxter's Enhanced Hemopatch Eliminates Surgery Prep Time with Room-Temperature Storage - Stock Titan
Geode Capital Management LLC Buys 290,279 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Wound Care Market to Witness Remarkable Growth with 3M, Baxter, - openPR.com
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Baxter International Inc.(BAX) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
Artificial Kidney Market to See Revolutionary Growth | Baxter - openPR.com
Baxter International Inc (BAX) Shares Down 3.27% on Apr 7 - GuruFocus
Citigroup Adjusts Baxter International Price Target to $35 From $37, Maintains Neutral Rating - MarketScreener
Baxter stock touches 52-week low at $28.22 amid market challenges - Investing.com Australia
Baxter stock touches 52-week low at $28.22 amid market challenges By Investing.com - Investing.com South Africa
Intravenous Solutions Market Is Booming Worldwide | Baxter - openPR.com
Allstate Corp Makes New $450,000 Investment in Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International (NYSE:BAX) CEO Change as Stock Dips 2% Last Quarter - Yahoo Finance
Baxter International Inc. (NYSE:BAX) Short Interest Update - MarketBeat
Healthcare: Policy Uncertainty Is Countered by Interest in Defensive Stocks - Morningstar
US hospitals strained by IV fluid supply limits after Helene hit production site - AOL.com
Evercore ISI Adjusts Baxter International Price Target to $45 From $44, Maintains Outperform Rating - MarketScreener
Baxter International Inc. (NYSE:BAX) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Baxter CEO pay surged before his departure — along with the median employee’s wage - Medical Design & Outsourcing
Finanzdaten der Baxter International Inc-Aktie (BAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.87%
0.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):